Center-Authored Papers

Filters: Author is Gulati, Roman  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, Boyer B, Mohatt GV.  2010.  Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos.. The American journal of clinical nutrition. 91(3):777-85. Abstract
Xenograft Model Antitumor Assays
Morrissey C, Lai JS, Brown LG, Wang Y-C, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E et al..  2010.  The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.. The Prostate. 70(4):412-24. Abstract
United States
Telesca D, Etzioni R, Gulati R.  2008.  Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.. Biometrics. 64(1):10-9. Abstract
Fesinmeyer MD, Gulati R, Zeliadt S, Weiss NS, Kristal AR, Etzioni R.  2009.  Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(3):808-15. Abstract
Etzioni R, Xia J, Hubbard R, Weiss NS, Gulati R.  2014.  A reality check for overdiagnosis estimates associated with breast cancer screening.. Journal of the National Cancer Institute. 106(12) Abstract
Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM.  2013.  Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.. Medical care. 51(4):295-300. Abstract
Etzioni R, Gulati R.  2013.  Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.. Medical care. 51(4):304-6. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Etzioni R, Gulati R, Falcon S, Penson DF.  2008.  Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.. Medical decision making : an international journal of the Society for Medical Decision Making. 28(3):323-31. Abstract
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Tumor Markers, Biological
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Telesca D, Etzioni R, Gulati R.  2008.  Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.. Biometrics. 64(1):10-9. Abstract
Triglycerides
Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, Boyer B, Mohatt GV.  2010.  Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos.. The American journal of clinical nutrition. 91(3):777-85. Abstract
Treatment Outcome
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract
Tissue Array Analysis
Morrissey C, Lai JS, Brown LG, Wang Y-C, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E et al..  2010.  The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.. The Prostate. 70(4):412-24. Abstract
Time Factors
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Etzioni R, Xia J, Hubbard R, Weiss NS, Gulati R.  2014.  A reality check for overdiagnosis estimates associated with breast cancer screening.. Journal of the National Cancer Institute. 106(12) Abstract
Telesca D, Etzioni R, Gulati R.  2008.  Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.. Biometrics. 64(1):10-9. Abstract
Tibia
Morrissey C, Lai JS, Brown LG, Wang Y-C, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E et al..  2010.  The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.. The Prostate. 70(4):412-24. Abstract
Testicular Neoplasms
Lewinshtein D, Gulati R, Nelson PS, Porter CR.  2012.  Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma.. BJU international. 109(5):706-12. Abstract
Survival Rate
Telesca D, Etzioni R, Gulati R.  2008.  Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.. Biometrics. 64(1):10-9. Abstract
Survival Analysis
Telesca D, Etzioni R, Gulati R.  2008.  Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.. Biometrics. 64(1):10-9. Abstract
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract
Shared Resources
Morrissey C, Lai JS, Brown LG, Wang Y-C, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E et al..  2010.  The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.. The Prostate. 70(4):412-24. Abstract